Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens
- 16 May 2011
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 87 (3), 217-227
- https://doi.org/10.1111/j.1600-0609.2011.01649.x
Abstract
Background: We have previously reported that serum interleukin‐18 (IL‐18) concentration predicted the clinical outcome of patients with aggressive non‐Hodgkin’s lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). When rituximab (R) was added to this regimen, the prognosis of diffuse large B‐cell lymphoma (DLBCL) was markedly improved. Patients and Methods: In this study, we re‐evaluated the prognostic significance of serum IL‐18 in 227 DLBCL patients. Seventy‐three patients received CHOP before R‐era, and 154 patients received rituximab‐cyclophosphamide, doxorubicin, vincristine, and prednisolone (R‐CHOP) recently. Result: Four‐year overall survival (4‐yr OS) rates for patients in CHOP group with IL‐18 ≥ 720 pg/mL and P < 0.0001), respectively, and 4‐yr OS rates with IL‐18 ≥ 590 and P = 0.0008), respectively. Multivariate analysis revealed that serum IL‐18 correlated most significantly with OS and progression‐free survival (PFS) in both groups (OS: P < 0.0001, PFS: P < 0.0001, in CHOP group; OS: P = 0.0147, PFS: P = 0.0084 in R‐CHOP group). The high serum IL‐18 patients with poor prognostic group in revised IPI or with non‐germinal center B‐cell phenotype had a very poor prognosis. Conclusion: Serum IL‐18 might be a powerful prognostic factor for DLBCL in R‐era.Keywords
This publication has 40 references indexed in Scilit:
- Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2008
- Germinal center B (GCB) and non‐GCB cell‐like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantationBritish Journal of Haematology, 2008
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Serum‐soluble tumor necrosis factor receptor 2 (sTNF‐R2) level determines clinical outcome in patients with aggressive non‐Hodgkin's lymphomaEuropean Journal of Haematology, 2006
- Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced CancerClinical Cancer Research, 2006
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyBlood, 2006
- Interleukin-18Journal of Leukocyte Biology, 2003
- Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and ImmunohistochemistryLaboratory Investigation, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- IGIF Does Not Drive Th1 Development but Synergizes with IL-12 for Interferon-γ Production and Activates IRAK and NFκBImmunity, 1997